Prostate cancer diagnostics using a non-invasive test based on innovative glycan-based scanning

Prostate cancer (PCa) is the 2nd most frequent cancer in men with 1.4M new annual cases and nearly 0.4M deaths worldwide in 2020. PCa incidence is expected to increase to 2.1M cases and 0.6M annual deaths by 2035. Statistically, 1 in 8 men will get PCa in their lifetime. However, nearly 50% of cancer deaths may be avoided if PCa were detected at early stages.

Survival is proportional to the stage reached at the time of diagnosis - hence early-stage diagnostics is key to reduce mortality.

Our aim is to clinically validate & register ProSCAN, an affordable, non-invasive next-generation liquid biopsy PCa diagnostic test with a final accuracy of up to 90%. The ProSCAN is the first test for early-stage PCa diagnostics based on glycan analysis in blood. ProSCAN will identify healthy men and those at risk of PCa, who need a confirmatory biopsy.

Being so accurate, ProSCAN will eliminate ~1.6 M of avoidable biopsies with the cost of ~1.5bn (in the EU and the US alone).